The effect of raleukin on the values of glucose homeostasis of normoglycemic rats in glucose load

Authors

  • I. P. Bukhtiyarova Donetsk National Medical University named after M.Gorky, Ukraine
  • S. M. Drogovoz National University of Pharmacy, Ukraine
  • O. M. Ischenko Research Institute of High-Purity Biopharmaceuticals, Ukraine
  • E. L. Toryanik Research Institute of High-Purity Biopharmaceuticals, Ukraine

DOI:

https://doi.org/10.24959/cphj.14.1269

Keywords:

Intraperitoneal and oral glucose tolerance test, hypoglycemic effect, raleukin

Abstract

Diabetes mellitus (DM) remains the only noncontagious disease for today, which prevalence, according to the World Health Organization, has reached epidemic proportions. According to the results of recent research proinflammatory cytokines, namely interleukin-1 (IL-1), play an important role in the pathogenesis of both types of diabetes. Therefore, drugs that can inhibit the activity of IL-1 by suppressing its receptors, improve survival and normalize the functional activity of β-cells of the pancreas are promising anti-diabetic agents. The article presents the results of the pharmacological screening of hypoglycemic properties of receptor antagonist IL-1 raleukin obtained in the Research Institute of High-Purity Biopharmaceuticals (St. Petersburg) in normoglycemic rats under conditions of tolerance tests to carbohydrates. It has been found that in the intraperitoneal glucose tolerance test the antagonist of IL-1 raleukin shows a significant hypoglycemic effect in the doses of 7 and 10 mg/kg, i.e. it is a promising antidiabetic agent. In the oral glucose tolerance test raleukin in the dose of 7 mg/kg revealed the same hypoglycemic activity. This dose is a conditionally effective dose of the drug by the hypoglycemic effect; it can be used in further studies of anti-diabetic properties of raleukin. The  results experimentally substantiate the high efficiency and expediency of IL-1 receptors blockade as one of the ways of correcting hyperglycemia in type 1 diabetes.

References

Балаболкин М.И., Клебанова Е.М., Креминская В.М. Лечение сахарного диабета и его осложнений. – М., 2005. – 512 с.

Дедов И.И. // Вестник Росс. академии мед. наук. – 2012. – №1. – С. 7-13.

Дедов И.И., Шестакова М.В. Сахарный диабет: Руководство для врачей. – М., 2003. – С. 151-175.

Доклінічні дослідження лікарських засобів: Метод. рекоменд. / За ред. чл.-кор. НАМН України О.В.Стефанова. – К.: Авіценна, 2001. – 528 с.

Симбирцев А.С. Медицинские препараты на основе белков семейства интерлейкина-1 / В кн.: Справочник по иммунотерапии для практического врача. – С.Пб.: Изд-во «Диалог», 2002. – С. 152-165.

Сунцов Ю.И., Болотская Л.Л., Маслова О.В. и др. // Сахарный диабет. – 2011. – №1. – С. 15-18.

Шумейко О.Г. Експериментальне обґрунтування застосування екстракту з мідії чорноморської (Mytilus galloprovincialis Lam.) у комплексній терапії цукрового діабету: Дис. … канд. мед. наук: 14.01.14 – ендокринологія. – Х., 2009. - 153 с.

Щокіна К.Г. Органотропні ефекти рекомбінантного антагоніста рецепторів інтерлейкіну-1 (експериментальне дослідження): Дис. … докт. фарм. наук: 14.03.05 – фармакологія. – Х., 2011. – 440 с.

Alexandraki K., Piperi C., Kalofoutis C. et al. // Ann. N. Y. Acad. Sci. – 2006. – Vol. 1084. – P. 89-117.

Andersson A.K., Borjesson A., Sandgren J. et al. // Mol. Cell Endocrinol. – 2005. – Vol. 240. – P. 50-57.

Börjesson A., Carlsson C. // J. Endocrinol. – 2007. – Vol. 192 (2). – P. 381-387.

Fève В., Bastard J.-P. // Nature Rev. Endocrinol. – 2009. – №5. – Р. 305-311.

Lagathu C., Yvan-Charvet L., Bastard J.P. et al. // Diabetol. – 2006. – №49. – Р. 2162-2173.

Larsen C.M., Faulenbach M., Vaag A. et al. // N. Engl. J. Med. – 2007. – Vol. 356. – P. 1517-1526.

Larsen C.M., Faulenbach M., Vaag A. et al. // Diabetes Care. – 2009. – Vol. 32. – P. 1663-1668.

Mandrup-Poulsen T., Bendtzen K., Dinarello C.A. et al. // J. Immunol. – 1987. – Vol. 139 (12). – P. 4077-4082.

World Health Organization. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus. Abbreviated report of a WHO consultation. – World Health Organization, 2011 (WHO/NMH/CHP/ CPM/11.1).

Downloads

Published

2014-06-10

Issue

Vol. 18 No. 2 (2014)

Section

Pre-clinical studies of new drugs

License

Copyright (c) 2014 National University of Pharmacy

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).